These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25490969)

  • 1. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
    Tembe V; Schramm SJ; Stark MS; Patrick E; Jayaswal V; Tang YH; Barbour A; Hayward NK; Thompson JF; Scolyer RA; Yang YH; Mann GJ
    Pigment Cell Melanoma Res; 2015 May; 28(3):254-66. PubMed ID: 25490969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
    Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
    J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
    Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
    Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
    Kim JH; Ahn JH; Lee M
    Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
    Jayawardana K; Schramm SJ; Tembe V; Mueller S; Thompson JF; Scolyer RA; Mann GJ; Yang J
    J Invest Dermatol; 2016 Jan; 136(1):245-254. PubMed ID: 26763444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.
    Schramm SJ; Li SS; Jayaswal V; Fung DC; Campain AE; Pang CN; Scolyer RA; Yang YH; Mann GJ; Wilkins MR
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):708-22. PubMed ID: 23738911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
    Sand M; Skrygan M; Sand D; Georgas D; Gambichler T; Hahn SA; Altmeyer P; Bechara FG
    Cell Tissue Res; 2013 Jan; 351(1):85-98. PubMed ID: 23111773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
    Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D
    Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
    Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
    Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
    Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
    Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
    Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
    Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-579-3p controls melanoma progression and resistance to target therapy.
    Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas.
    Valentini V; Zelli V; Gaggiano E; Silvestri V; Rizzolo P; Bucalo A; Calvieri S; Grassi S; Frascione P; Donati P; Soda G; Ottini L; Richetta AG
    Anticancer Res; 2019 Aug; 39(8):4085-4093. PubMed ID: 31366492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA expression profiling and Notch1 and Notch2 expression in minimal deviation adenocarcinoma of uterine cervix.
    Lee H; Kim KR; Cho NH; Hong SR; Jeong H; Kwon SY; Park KH; An HJ; Kim TH; Kim I; Yoon HK; Suh KS; Min KO; Choi HJ; Park JY; Yoo CW; Lee YS; Lee HJ; Lee WS; Park CS; Lee Y;
    World J Surg Oncol; 2014 Nov; 12():334. PubMed ID: 25381598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
    Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
    Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signatures of microRNAs and selected microRNA target genes in human melanoma.
    Philippidou D; Schmitt M; Moser D; Margue C; Nazarov PV; Muller A; Vallar L; Nashan D; Behrmann I; Kreis S
    Cancer Res; 2010 May; 70(10):4163-73. PubMed ID: 20442294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.